Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer

Marcos Aurélio Fonseca Magalhães(Faculdade de Medicina do ABC), Auro del Giglio(Faculdade de Medicina do ABC), Milena Brachmans Mascarenhas Neves(Faculdade de Medicina do ABC), Pedro Nazareth Aguiar(Sociedade Brasileira de Oncologia Clínica), Gilberto Lopes(University of Miami)

Einstein (São Paulo)

January 1, 2022

10.31744/einstein_journal/2022gs6655

Cited by 8

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

|The Lancet|2020|1.8k

Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications

|Photodiagnosis and Photodynamic Therapy|2005|910

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

|Journal of Clinical Oncology|2022|334

The biology of cancer-related fatigue: a review of the literature

|Supportive Care in Cancer|2015|305